PEG-Interferon lambda (IL-29) is a novel and first in class interferon in development for hepatitis C. The native human interferon lambda proteins are generated by the immune system in response to ...
A single injection of an experimental biologic drug may cut in half your risk of hospitalization from COVID-19 infection, new clinical trial results show. Pegylated lambda interferon (PEG-lambda) ...
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in ...
Bristol-Myers Squibb and ZymoGenetics reported that the administration of the investigational compound PEG-Interferon lambda in combination with ribavirin significantly reduced hepatitis C virus (HCV) ...
PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with ...
April 11, 2011 (Berlin, Germany) — Pegylated interferon lambda (Peg-IFN lambda) showed virological responses superior to the standard of care, pegylated interferon alfa-2a (Peg-IFN alfa-2a), when ...
ZymoGenetics, Inc. has announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback